Loading...
XSTO
ACARIX
Market cap29mUSD
Jul 09, Last price  
0.26SEK
1D
0.39%
1Q
-12.73%
Jan 2017
-98.35%
IPO
-97.65%
Name

Acarix AB

Chart & Performance

D1W1MN
XSTO:ACARIX chart
P/E
P/S
39.22
EPS
Div Yield, %
Shrs. gr., 5y
60.28%
Rev. gr., 5y
27.67%
Revenues
7m
+18.69%
000638,0001,024,0001,857,0002,170,0003,760,0005,822,0006,241,0006,202,0007,361,000
Net income
-48m
L-27.34%
-19,209,000-12,393,000-48,240,000-29,776,000-42,271,000-46,459,000-41,548,000-51,802,000-76,985,000-77,839,000-66,187,000-48,091,000
CFO
-48m
L-23.60%
-20,871,000-8,631,000-9,056,000-40,539,000-38,609,000-44,533,000-36,686,000-48,007,000-74,869,000-81,366,000-63,325,000-48,383,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Acarix AB (publ) is a medical technology company that develops and introduces diagnostic solutions for cardiovascular conditions to markets including Germany, Sweden, the Middle East, Switzerland, Austria, and globally. Their key product is the CADScor System, an exceptionally sensitive, non-invasive analytical device designed for the detection of coronary artery disease. Founded in 2009, Acarix AB (publ) maintains its headquarters in Malmö, Sweden.
IPO date
Dec 19, 2016
Employees
20
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT